COMPANY PROFILE

Elektrofi

A biotechnology company focused on improving administration for a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs

Boston, United StatesFounded 2016Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2025

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Elektrofi

Elektrofi specializes in the formulation and delivery of biologic drugs, focusing on high concentration, low syringe force protein formulations. These formulations can be administered in small volumes via simple subcutaneous injections, significantly reducing the time required for drug delivery from hours to just seconds. This innovation addresses the discomfort, inconvenience, and infection risks associated with traditional intravenous infusions, while also reducing healthcare costs. Elektrofi's primary clients include patients, healthcare providers, and payers. The company operates in the biopharmaceutical market, leveraging its proprietary technology platform to create value. Elektrofi generates revenue through partnerships and the commercialization of its advanced drug delivery solutions.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2016
Headquarters: Boston, United States
Employees: 41
Open positions: 4
Dealroom signal: 61.9/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

7 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITIONOther financing	Oct 2025	$750M	$750M	Halozyme Therapeutics	↗
SERIES COther financing	Aug 2024	$112M	$448M	Janus Henderson Investors · Andera Partners · Marshall Wace	—

Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Elektrofi website traffic

Latest recorded traffic for Elektrofi is 2.4K monthly website visits, up 50% over the last three months. Elektrofi's team declined 58.6% over the past year.

Latest monthly visits2.4K 3-month web change+50% 1-year team growth-58.6%

Monthly website visitsOct 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Director, Analytical DevelopmentBoston, MA · Business Intelligence · Sep 5, 2026 Senior Director, Alliance ManagementBoston, MA · Project Management · Aug 27, 2026 Manager, ITBoston, MA · Other · Jul 23, 2026 Senior Engineer II, MS&TBoston, Massachusetts, United States, Northern America, Americas · Other · Jul 21, 2026 Senior Engineer II, Manufacturing Science and TechnologyBoston, MA · Other · Jul 18, 2026 Research Associate, Analytical DevelopmentBoston, MA · Other · Jun 30, 2026 Senior Director, CMC Technical LeadBoston, Massachusetts, United States · Human Resources · Jan 9, 2026

7 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
HTHalda TherapeuticsPrecision oncology therapies targeting cancer via RIPTAC™ chimera	New Haven, United States	Acquired	40	$126M	$3B
DBDiffuse BioWe're building push-button software for drug design, driven by breakthroughs in generative AI	San Francisco, United States	Operational
TTTafalgie TherapeuticsNext-generation pain management treatments derived from an endogenous secreted protein capable of modulating pain signals	Marseille, France	Operational
MAMatchpointDesigning a new era of precision covalent medicines informed by breakthroughs in ultradeep chemoproteomics and machine learning	Boston, United States	Operational
ATApertura Gene TherapyLeverages ML to engineer novel capsids, gene regulatory elements to simultaneously enhance gene therapies	New York City, United States	Operational
RORadionetics OncologyRadionetics Oncology is a precision oncology company focusing on the discovery and development of radiopharmaceuticals	San Diego, United States	Operational
NBNabla BioDeveloping AI and wet-lab technologies to enable the rational design of selective, functional drugs targeting previously undruggable sites	Cambridge, United States	Operational
ABAtavistik BioPrecision allosteric therapeutics for oncology and rare diseases.	Cambridge, United States	Operational